

Evaluation of Sexual Dysfunction and Related Factors in Iranian Men with Type 2 Diabetes: A Cross-Sectional Study

Morteza Mirdehghan¹, Nastaran Injinari¹, Mahmoud Vakili², Nasim Namiranian^{1*}

¹Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

²Department of Community and Preventive Medicine, Health Monitoring Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Abstract

Objective: Recently, the association between sexual dysfunction (SD) and diabetes has been proven in various studies. The study aimed to determine the frequency of SD and identify risk factors related to SD in men with Type 2 diabetes mellitus (T2DM).

Materials and Methods: The cross-sectional study was conducted on 114 men with T2DM who had referred to the Yazd Diabetes Center from 2019-2020. All of them filled out a standard questionnaire with a specified validity and reliability. The analysis was performed using ANOVA and Chi-square by SPSS, version 22 software.

Results: The mean age of participants was 52.48 (± 5.33). The SD frequency was 73.7%. The mean SD score was 17.89 (± 12). There was a significant relationship between the total SD and neuropathy ($P: 0.0001$), retinopathy ($P: 0.0001$), nephropathy ($P: 0.023$), type of treatment ($P: 0.0001$), age ($P: 0.0001$) and addiction ($P: 0.031$). There was no significant relationship between the total SD score and hyperlipidemia ($P: 0.371$), hypertension ($P: 0.683$), Hb1Ac ($P: 0.816$), duration of diabetes ($P: 0.101$) and smoking ($P: 0.29$).

Conclusion: Due to the high frequency of sexual dysfunction in men with T2DM, it is recommended that SD be considered as an important complication in these patients so that by identifying indicators related to this complication in patients with diabetes, sexual health clinics take the necessary measures to solve sexual problems in these patients.

Keywords: Type 2 diabetes mellitus, Men, Sexual dysfunction

QR Code:



Citation: Mirdehghan M, Injinari N, Vakili M, Namiranian N. Evaluation of Sexual Dysfunction and Related Factors in Iranian Men with Type 2 Diabetes: A Cross-Sectional Study. IJDO 2023; 15 (1) :25-33

URL: <http://ijdo.ssu.ac.ir/article-1-775-en.html>



10.18502/ijdo.v15i1.12208

Article info:

Received: 01 December 2022

Accepted: 09 February 2023

Published in March 2023



This is an open access article under the (CC BY 4.0)

Corresponding Author:

Nasim Namiranian, Associate Professor, Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Tel: (98) 353 728 0215

Email: namiranian.nasim@gmail.com

Orcid ID: 0000-0002-5133-6204

Introduction

Sexual dysfunction (SD) define as sexual impotence in successful sexual intercourse with a sexual partner (1). SD is one of the most factors that affect the quality of life. Effective factors such as obesity, alcohol, some medications, and some diseases have been identified that lead to male sexual disorder (2).

Nowadays, among the disease factors, diabetes has attracted a lot of attention among researchers. It is estimated that the global diabetes prevalence was 9.3% in 2019 (3). In Iran, 11/4% of the population over the age of 25 had diabetes in 2011, and it has estimated in 2030, 9.2 million Iranians will have diabetes (4). The prevalence of diabetes in Yazd, is so high and it is estimated that one in five adults suffer from diabetes (5).

Diabetes and poor glycemic control, for a long time, will cause micro and macrovascular complication (6). Retinopathy, nephropathy, and neuropathy are classified as microvascular complications, and ischemic heart disease and stroke are classified as macrovascular complications (7,8). To prevent complications of diabetes, it is necessary to have accurate information about the disease (9).

It is reported that men with type 2 diabetes mellitus (T2DM) may experience SD and results in erectile dysfunction, hypogonadism, ejaculatory dysfunction, and sexual desire dysfunction (10). SD occurs in diabetics in both physical and psychological forms. Mental disorders are caused by decreased sexual desire, decreased irritability, and decreased self-confidence, as well as decreased marital satisfaction. Physical disorders include autonomic neuropathy, hormonal disorders, atherosclerosis, and vascular insufficiency (11-13).

It is estimated that 51.3% of men with diabetes suffer from ejaculation dysfunction. Important factors such as vascular insufficiency, neuropathy, and under expression of vascular endothelial growth

factor (VEGF), lead to diabetes-related ejaculation dysfunction (2).

SD is one of the major concerns for diabetic patients and identifying the effective factors related to sexual domains is essential to the management of diabetes. Some literature has reported that age, duration of diabetes, depressive symptoms, and some anti-diabetic drugs play a role in sexual dysfunction in men with T2DM (10,14). In 2019, Adane et al reported that physical inactivity, depression, and having complications are significantly related to SD in diabetic patients (15).

SD is extremely common not only in men with type 2 diabetes but also in pre-diabetic men (16). On the other hand, in developing countries, sexual dysfunction is not seen as a complication of diabetes and there is no strategy for this complication in diabetic patients (17). In this study, we measured the frequency of SD in men with T2DM, and then SD-related factors in them were assessed.

Materials and Methods

Research design

In the cross-sectional study, convenience sampling method was done, and 114 T2DM patients from 2019-2020 who referred to the Yazd Diabetes Center, were studied. All patients met the following inclusion criteria: type 2 diabetes lasting for at least two years, age 35-60 years, married and cohabitation, no alcohol addiction, and satisfaction with participation in the study. The exclusion criteria were: having neurological diseases, history of performing surgeries on genitals, the existence of severe physical disabilities or disabilities of oneself or partner, consumption of known drugs that affect sexual function (increasing or decreasing), and the existence of known chronic diseases affecting sexual function such as cardiovascular disease and cancer. Blood pressure $>80/135$ as hypertension and triglycerides > 250 as hyperlipidemia were regarded. Moreover,

drugs included opium, morphine, codeine, and tramadol.

Questionnaire

To evaluating sexual function in participants, a standard questionnaire with a specified validity and reliability was used (18). Based on patients' self-report, a checklist related to the studied contextual variables such as patients' demographics was used. In the second part of the questionnaire, the International Index of Erectile Function (IIEF) was assessed in five domains: erectile, orgasm, sexual desire, the satisfaction of intercourse, and overall satisfaction. The final analysis of the questionnaire was performed in the form of a general score and components of the questionnaire. The total score was regarded from 15 to 75 and based on the sexual function the patients were categorized into dysfunction (15-20), moderate function (25-50), and good function (>50).

Statistical analysis

The Kolmogorov-Smirnov test was used to assess the normality of distribution. The chi-square test was used for relationship between clinical symptoms and addiction with sexual function. The ANOVA test was used for relationship between age and HbA1c with domains of sexual function. All statistical analysis was performed using SPSS, version

22 software, and P less than 0.05 ($P < 0.05$) was considered significant.

Ethical considerations

The protocol used in this study was approved by the ethics committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran. (IR.SSU.MEDICINE.REC.1397.195)

Results

Baseline characteristics of participants

The demography and clinical characteristics are summarized in Table 1. The mean age of participants was 52.48 (± 5.33), the mean HbA1c value was 7.76 (± 1.07) and the mean smoking (pack/year) obtained 4.49 (± 10.32). None of the subjects had thyroid disease.

Assessment of sexual function in the diabetic population

As shown in Table 2, based on the total IIEF score, 73.7% of patients with T2DM were in a state of SD.

Sexual dysfunction in participants and its related factors

The correlation of studied variables with five sexual domains to the etiology of sexual dysfunction in men with T2DM is shown in the following tables (Tables 3,4).

Table 1. Demographic and clinical data of the participants

Variable	Frequency (%), n:114	
Job	Government employee	6 (5.3%)
	Private employee	66 (57.9%)
	Retired	38 (33.3%)
	Unemployed	4 (3.5%)
	Illiterate	8 (7%)
Education	Primary	38 (33.3%)
	Middle school	32 (28.1%)
	High school	14 (12.3%)
	Diploma	16 (14.0%)
	Associate Degree	6 (5.3%)
Blood sugar treatment	Oral	58 (50.9%)
	Insulin	56 (49.1%)
Neuropathy	90 (78.9%)	
Retinopathy	60 (52.6%)	
Nephropathy	12 (10.5%)	
Hyperlipidemia	80 (70.2%)	
Hypertension	72 (63.2%)	
Drug Addiction	29 (25.4%)	

There was a significant relationship between the total IIEF score and neuropathy (P : 0.0001), retinopathy (P : 0.0001), nephropathy (P : 0.023), type of treatment (P : 0.0001), age (P : 0.0001), and addiction (P : 0.031). On the

contrary, there was no significant relationship between the total IIEF score and hyperlipidemia (P : 0.371), hypertension (P : 0.683), Hb1Ac (P : 0.816), duration of diabetes (P : 0.101), and smoking (P : 0.29).

Table 2. Sexual function in patients with type 2 diabetes

Domain		Frequency (%), n:114
Overall sexual function	Dysfunction	84 (73.7%)
	Moderate function	12 (10.5%)
	Good function	18 (15.8%)
Orgasm	Dysfunction	78 (68.4%)
	Moderate function	22 (19.3%)
	Good function	14 (12.3%)
Sexual desire	Dysfunction	96 (84.2%)
	Moderate function	18 (15.8%)
	Good function	0 (0%)
Overall satisfaction	Dysfunction	94 (82.5%)
	Moderate function	20 (17.5%)
	Good function	0 (0%)
Erectile	Dysfunction	82 (71.9%)
	Moderate function	22 (19.3%)
	Good function	10 (8.8%)
Intercourse satisfaction	Dysfunction	90 (78.9%)
	Moderate function	22 (19.3%)
	Good function	2 (1.8%)

Table 3. Correlation of patients' clinical symptoms with sexual domains

Sexual domains		Frequency		P
		Yes	No	
Neuropathy				
Total score	Dysfunction	74 (66%)	10 (8%)	0.0001*
	Moderate function	2 (2%)	10 (8%)	
	Good function	14 (12%)	4 (3%)	
Orgasm	Dysfunction	68 (62%)	10 (8%)	0.0001*
	Moderate function	10 (8%)	12 (10%)	
	Good function	12 (10%)	2 (2%)	
Sexual desire	Dysfunction	76 (67%)	20 (18%)	0.894
	Moderate function	14 (12%)	4 (3%)	
	Good function	0	0	
Overall satisfaction	Dysfunction	78 (69%)	16 (14%)	0.022*
	Moderate function	12 (10%)	8 (7%)	
	Good function	0	0	
Erectile	Dysfunction	72 (64%)	10 (8%)	0.0001*
	Moderate function	8 (7%)	14 (13%)	
	Good function	10 (8%)	0	
Intercourse satisfaction	Dysfunction	74 (65%)	16 (14%)	0.121
	Moderate function	14 (13%)	8 (7%)	
	Good function	2 (2%)	0	
Retinopathy				
Total score	Dysfunction	54 (47%)	30 (26%)	0.0001*
	Moderate function	2 (2%)	10 (8%)	
	Good function	14 (13%)	4 (4%)	
Orgasm	Dysfunction	50 (44%)	28 (25%)	0.001*
	Moderate function	6 (5%)	16 (15%)	
	Good function	4 (3%)	10 (8%)	

Continued

Sexual domains		Frequency		<i>p</i>
		Yes	No	
Retinopathy				
Sexual desire	Dysfunction	56 (50%)	40 (35%)	0.005*
	Moderate function	4 (3%)	14 (12%)	
	Good function	0	0	
Overall satisfaction	Dysfunction	54 (46%)	40 (35%)	0.026*
	Moderate function	6 (5%)	14 (12%)	
	Good function	0	0	
Erectile	Dysfunction	52 (45%)	30 (28%)	0.001*
	Moderate function	8 (7%)	14 (12%)	
	Good function	4 (3%)	6 (5%)	
Intercourse satisfaction	Dysfunction	54 (46%)	36 (32%)	0.007*
	Moderate function	6 (5%)	16 (15%)	
	Good function	0	2 (2%)	
Nephropathy				
Total score	Dysfunction	7 (6%)	77 (68%)	0.023*
	Moderate function	0	12 (10%)	
	Good function	5 (5%)	13 (11%)	
Orgasm	Dysfunction	6 (5%)	72 (63%)	0.265
	Moderate function	3 (2.5%)	19 (16%)	
	Good function	3 (2.5%)	11 (11%)	
Sexual desire	Dysfunction	7 (6%)	89 (78%)	0.009*
	Moderate function	5 (5%)	13 (11%)	
	Good function	0	0	
Overall satisfaction	Dysfunction	7 (6%)	87 (75%)	0.020*
	Moderate function	5 (5%)	15 (14%)	
	Good function	0	0	
Erectile	Dysfunction	7 (6%)	75 (65%)	0.110
	Moderate function	2 (2%)	20 (17%)	
	Good function	3 (3%)	7 (7%)	
Intercourse satisfaction	Dysfunction	7 (7%)	83 (73%)	0.109
	Moderate function	5 (5%)	17 (14%)	
	Good function	0	2 (1%)	
Hyperlipidemia				
Total score	Dysfunction	56 (50%)	28 (24%)	0.371
	Moderate function	10 (8%)	2 (2%)	
	Good function	14 (12%)	4 (4%)	
Orgasm	Dysfunction	50 (44%)	28 (24%)	0.110
	Moderate function	18 (16%)	4 (4%)	
	Good function	12 (10%)	2 (2%)	
Sexual desire	Dysfunction	66 (58%)	30 (26%)	0.442
	Moderate function	14 (12%)	4 (4%)	
	Good function	0	0	
Overall satisfaction	Dysfunction	64 (56%)	30 (26%)	0.290
	Moderate function	16 (14%)	4 (4%)	
	Good function	0	0	
Erectile	Dysfunction	54 (47%)	28 (24%)	0.270
	Moderate function	18 (16%)	4 (4%)	
	Good function	8 (7%)	2 (2%)	
Intercourse satisfaction	Dysfunction	62 (54%)	28 (24%)	0.610
	Moderate function	16 (14%)	6 (6%)	
	Good function	2 (2%)	0	
Hypertension				
Total score	Dysfunction	55 (48%)	29 (26%)	0.683
	Moderate function	7 (6%)	5 (5%)	
	Good function	10 (8%)	8 (7%)	

Continued

Sexual domains		Frequency		P
		Yes	No	
Hypertension				
Orgasm	Dysfunction	51 (44%)	27 (24%)	0.763
	Moderate function	13 (11%)	9 (8%)	
	Good function	8 (7%)	6 (6%)	
Sexual desire	Dysfunction	62 (55%)	34 (29%)	0.466
	Moderate function	10 (9%)	8 (7%)	
	Good function	0	0	
Overall satisfaction	Dysfunction	58 (51%)	36 (31%)	0.485
	Moderate function	14 (12%)	6 (6%)	
	Good function	0	0	
Erectile	Dysfunction	54 (48%)	28 (24%)	0.561
	Moderate function	13 (11%)	9 (7%)	
	Good function	5 (5%)	5 (5%)	
Intercourse satisfaction	Dysfunction	60 (53%)	30 (26%)	0.100
	Moderate function	10 (8%)	12 (11%)	
	Good function	2 (2%)	0	
Type of treatment				
Total score		Oral	Insulin	0.0001*
	Dysfunction	32 (28%)	52 (45%)	
	Moderate function	12 (11%)	0	
Orgasm	Good function	14 (13%)	4 (3%)	0.004*
	Dysfunction	32 (28%)	46 (40%)	
	Moderate function	14 (13%)	8 (7%)	
Sexual desire	Good function	12 (11%)	2 (1%)	0.013*
	Dysfunction	44 (38%)	52 (46%)	
	Moderate function	14 (13%)	4 (3%)	
Overall satisfaction	Good function	0	0	0.004*
	Dysfunction	42 (36%)	52 (47%)	
	Moderate function	16 (14%)	4 (3%)	
Erectile	Good function	0	0	0.0001*
	Dysfunction	32 (28%)	50 (42%)	
	Moderate function	18 (16%)	4 (3%)	
Intercourse satisfaction	Good function	8 (7%)	2 (2%)	0.001*
	Dysfunction	38 (32%)	52 (47%)	
	Moderate function	18 (16%)	4 (3%)	
	Good function	2(2%)	0	

*The Chi-square test was used to analyze the data.

* Significant

Discussion

This study was conducted to evaluate the frequency of SD and SD-related factors in men with T2DM. SD influences the quality of life as well as can threaten the health of society (2,19). Recent studies demonstrated that SD is very common in men with T2DM (2,14,20). The cooperation of the central nervous system and peripheral neurotransmitters is critical to erection and ejaculation, and a factor such as anxiety, which is higher in patients with diabetes, disrupt this cooperation (11,21). Therefore, it makes sense for physicians to pay more attention to this complication in diabetic patients'. Our findings confirm previous studies and demonstrate that 73.7 % of men with T2DM suffer from SD. Among the five

domains of sexual function, erectile dysfunction is common in diabetic patients (15,22). Bahar et al. reported that 62.5 % of men with T2DM had erectile dysfunction in Iran (23). In another study in the U.S, Selvin et al. reported erectile dysfunction occurs in more than 50% of male diabetic patients (24).

Our results revealed that the occurrence of sexual desire dysfunction and erectile dysfunction were 84.2% and 71.9% respectively. One of the reasons for erectile dysfunction and decreased sexual desire is hypogonadism (25). It has been reported that hypogonadism is common in men with T2DM (26). Giovanni et al demonstrated that the use of Phosphodiesterase type 5 inhibitors (PDE5i), as an erectile dysfunction drug, can

Table 4. The relationship between sexual function and addiction in the diabetic population

Sexual domains		Frequency Addiction		<i>P</i>
		Yes	No	
Total score	Dysfunction	18 (15%)	66 (59%)	0.031*
	Moderate function	2 (2%)	10 (8%)	
	Good function	9 (8%)	9 (8%)	
orgasm	Dysfunction	16 (14%)	62 (54%)	0.157
	Moderate function	7 (6%)	15 (14%)	
	Good function	6 (5%)	8 (7%)	
Sexual desire	Dysfunction	22 (19%)	74 (64%)	0.153
	Moderate function	7 (6%)	11 (10%)	
	Good function	0	0	
Overall satisfaction	Dysfunction	20 (17%)	74 (64%)	0.027*
	Moderate function	9 (8%)	11 (10%)	
	Good function	0	0	
Erectile	Dysfunction	16 (15%)	66 (60%)	0.013*
	Moderate function	11 (10%)	11 (10%)	
	Good function	2 (2%)	8 (7%)	
Intercourse satisfaction	Dysfunction	20 (17%)	70 (62%)	0.139
	Moderate function	9 (8%)	13 (11%)	
	Good function	0	2 (2%)	

*Addiction includes opium, morphine, codeine, and tramadol. The chi-square test was used for the variable of addiction.

* Significant

boost sexual function and reduce the symptoms of depression in men with T2DM (27). Therefore, this disease can be better managed by further research and finding effective factors in sexual dysfunction in men with diabetes.

Several studies showed a higher risk of SD with a higher age in men and women with diabetes (2,15). Among the participants, based on a total score of IIEF, the age was remarkably associated with SD. Although SD in men and women increases with age (28), a comparison of men and women with diabetes to healthy people showed SD increases with age in patients with type 2 diabetes compared to the control group (14).

Smoking is linked to sexual dysfunction in both non-diabetics and diabetics (29,30). In our study smoking, HbA1c, and duration of diabetes were not predictors of SD. Based on Mark's study, the duration and extent of smoking are associated with sexual dysfunction (31). This can be examined in future studies by dividing consumption by pack/year. On the contrary, addiction, as well as the diabetic patients' type of treatment, was associated with their SD. Bahar et al. by

researching on 350 men with T2DM, reported that based on the IIEF total score, SD had been associated with age, as well as the type of treatment and there had no significant relation between SD with HbA1c (23).

Increasing evidence suggested that hypertension, as well as hyperlipidemia, leads to SD especially erectile dysfunction (2,32,33). Evaluating important cardiovascular risk factors including hypertension and hyperlipidemia, there was no significant relationship between any of the sexual domains and hypertension as well as hyperlipidemia in men with T2DM. These findings were consistent with Sharifi's study. Based on Sharifi's study on 200 men with T2DM, there were no significant associated with blood pressure and levels of triglycerides (34). On the contrary, a study on men with T2DM showed hypertension decreases the IIEF mean score, and those not had hypertension reported better sexual function significantly (23). To the best of our knowledge, no study has ever evaluated the association between sexual dysfunction and diabetes complications including neuropathy, retinopathy, and nephropathy in men with type

2 diabetes in Iran. Interestingly, the results of our study showed based on a total score of IIEF, there is a significant relationship between neuropathy, retinopathy, and nephropathy with SD.

Conclusions

Based on our study, the frequency of SD in studied men with T2DM was high. Parameters such as neuropathy, retinopathy, nephropathy, type of treatment, age, and addiction were correlated with SD. Therefore, it is suggested that physicians pay special attention to this disorder in diabetic men and by conducting more studies and assessing more predictors for sexual dysfunction, establish sexual health

clinics, like other clinics that treat microvascular complications of diabetes, and perform sexual counseling for these patients.

Acknowledgments

The protocol used in this study was approved by the ethics committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Conflict of Interest

No conflict of interest has been declared by the authors.

References

1. Leeners B, Tschudin S, Wischmann T, Kalaitzopoulos DR. Sexual dysfunction and disorders as a consequence of infertility: a systematic review and meta-analysis. *Human Reproduction Update*. 2023;29(1):95-125.
2. Chen L, Shi GR, Huang DD, Li Y, Ma CC, Shi M, et al. Male sexual dysfunction: A review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention. *Biomedicine & Pharmacotherapy*. 2019;112:108585.
3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. *Diabetes research and clinical practice*. 2019;157:107843.
4. Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, Saadat M, Esfahani EN, Ganji M, Noshad S, Khajeh E. Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). *Scientific reports*. 2017;7(1):1-0.
5. Mirzaei M, Rahmanian M, Mirzaei M, Nadjarzadeh A, Dehghani Tafti AA. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study. *BMC public health*. 2020;20:1-9.
6. Farhadi Z, Khaksari M. A Review on 17- β estradiol a Potent Therapeutic Factor of Diabetic Cardiomyopathy. *Iranian Journal of Diabetes and Obesity*. 2022 ;14(3):183-8.
7. Pearce I, Simó R, Lövestam-Adrian M, Wong DT, Evans M. Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review. *Diabetes, obesity and metabolism*. 2019;21(3):467-78.
8. Bekele BB. The prevalence of macro and microvascular complications of DM among patients in Ethiopia 1990–2017: Systematic review. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2019;13(1):672-7.
9. Aboutorabi-Zarchi M, Jam Ashkezari S, Gholami S, Razavi-Ratki SK, Namiranian N. Is Knowledge of type 2 diabetic patients about stroke acceptable-a cross sectional study. *Iranian Journal of Diabetes and Obesity*. 2019;11(1):22-7.
10. Isidro ML. Sexual dysfunction in men with type 2 diabetes. *Postgraduate medical journal*. 2012;88(1037):152-9.
11. Sharma JK, Rohatgi A, Sharma D. Diabetic autonomic neuropathy: a clinical update. *Journal of the Royal College of Physicians of Edinburgh*. 2020;50(3):269-73.
12. Gandhi J, Dagur G, Warren K. Effect of diabetes mellitus on sexual arousal and intercourse. *Transl Biomed*. 2016;7(2):2-5.
13. Firouzkouhi M, Abdollahimohammad A. Lived Experiences of Type 2 Diabetes with Irreversible Complications: A Qualitative Research. *Iranian Journal of Diabetes and Obesity*. 2022;14(3):176-82.
14. Bąk E, Marcisz C, Krzemińska S, Dobrzym-Matusiak D, Foltyn A, Drosdzol-Cop A. Relationships of sexual dysfunction with depression and acceptance of illness in women and men with type 2 diabetes mellitus. *International journal of*

- environmental research and public health. 2017;14(9):1073.
15. Asefa A, Nigussie T, Henok A, Mamo Y. Prevalence of sexual dysfunction and related factors among diabetes mellitus patients in Southwest Ethiopia. *BMC endocrine disorders*. 2019;19(1):1-8.
 16. Boeri L, Capogrosso P, Ventimiglia E, Schifano N, Montanari E, Montorsi F, et al. Sexual dysfunction in men with prediabetes. *Sexual medicine reviews*. 2020 ;8(4):622-34.
 17. Garza-Gangemi AM, Sotomayor-de Zavaleta M. Erectile dysfunction therapy in countries where implant is economically not feasible. *Translational Andrology and Urology*. 2017;6(2):176.
 18. Rahimi M, Reshadat S, Farid Marandi B, Zakiei A. Factors associated with sexual function and sexual satisfaction in male patients with diabetes type 2. *Journal of Mazandaran University of Medical Sciences*. 2018;28(164):164-9. (in Persian)
 19. Lombard A, Duffau H. Sexual dysfunction of patients with diffuse low-grade glioma: a qualitative review of a neglected concern. *Cancers*. 2022;14(12):3025.
 20. Alikamali M, Khodabandeh S, Motesaddi M. Sexual dysfunction in males and females with type 2 diabetes referring to healthcare centers of Zarand, Kerman: a cross-sectional study. *Shiraz E-Medical Journal*. 2019;20(8).
 21. Chandrashekar V, Steger RW, Bartke A, Fadden CT, Kienast SG. Influence of diabetes on the gonadotropin response to the negative feedback effect of testosterone and hypothalamic neurotransmitter turnover in adult male rats. *Neuroendocrinology*. 1991;54(1):30-5.
 22. Fallahi M, Mozaffari-Khosravi H, Afkhami-Ardekani M, Dehghani A. Evaluation of sexual function in men with diabetes mellitus type 2-Yazd Diabetes Research Center. *Iranian Journal of Diabetes and Obesity*. 2014;6(3):136-41.
 23. Bahar A, Elyasi F, Moosazadeh M, Afradi G, Kashi Z. Sexual dysfunction in men with type II diabetes. *Caspian Journal of Internal Medicine*. 2020;11(3):295.
 24. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. *The American journal of medicine*. 2007;120(2):151-7.
 25. Rizk PJ, Kohn TP, Pastuszak AW, Khera M. Testosterone therapy improves erectile function and libido in hypogonadal men. *Current opinion in urology*. 2017;27(6):511.
 26. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. *International journal of impotence research*. 2006;18(2):190-7.
 27. Corona G, Giorda CB, Cucinotta D, Guida P, Nada E, Subito-De Study Group. Sexual dysfunction in type 2 diabetes at diagnosis: progression over time and drug and non-drug correlated factors. *PLoS one*. 2016;11(10):e0157915.
 28. Camacho ME, Reyes-Ortiz CA. Sexual dysfunction in the elderly: age or disease?. *International journal of impotence research*. 2005;17(1):S52-6.
 29. Sahin MO, Sen V, Gunduz G, Ucer O. Effect of smoking cessation on sexual functions in men aged 30 to 60 years. *International braz j urol*. 2020;46:642-8.
 30. Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: current perspectives. *Diabetes, metabolic syndrome and obesity: targets and therapy*. 2014;7:95.
 31. Biebel MG, Burnett AL, Sadeghi-Nejad H. Male sexual function and smoking. *Sexual medicine reviews*. 2016;4(4):366-75.
 32. Heikkilä A, Kaipia A, Venermo M, Kautiainen H, Korhonen P. Relationship of blood pressure and erectile dysfunction in men without previously diagnosed hypertension. *The Journal of Sexual Medicine*. 2017;14(11):1336-41.
 33. Foy CG, Newman JC, Berlowitz DR, Russell LP, Kimmel PL, Wadley VG, et al. Blood pressure, sexual activity, and erectile function in hypertensive men: baseline findings from the Systolic Blood Pressure Intervention Trial (SPRINT). *The journal of sexual medicine*. 2019;16(2):235-47.
 34. Sharifi F, Asghari M, Jaberi Y, Salehi O, Mirzamohammadi F. Independent predictors of erectile dysfunction in type 2 Diabetes mellitus: Is it true what they say about risk factors?. *International Scholarly Research Notices*. 2012;2012:1-5.